Loading...All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
CD300A, encoded by the CD300A gene located at human chromosome 17q25.1, is a single-pass type I transmembrane receptor of the immunoglobulin superfamily. Its extracellular region contains a single immunoglobulin-like V-type domain, and its cytoplasmic tail carries immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The protein has a calculated molecular weight of approximately 33 kDa, and it is expressed on a range of immune cells, including natural killer cells, T cells, B cells, and myeloid cells. Rather than activating immune responses, CD300A functions as an inhibitory receptor that transmits negative signals upon ligand engagement. It binds the aminophospholipids phosphatidylethanolamine and phosphatidylserine, which are exposed on the surface of apoptotic and activated cells, and its ligation recruits the SHP-1 and SHP-2 phosphatases to suppress immune cell activation.
CD300A is an inhibitory receptor that participates in the negative regulation of immune cell responses. Its ITIM-mediated signaling inhibits natural killer cell cytotoxicity, B cell and T cell receptor signaling, and mast cell degranulation, and it modulates the engulfment of apoptotic cells by myeloid cells. Through these activities, CD300A contributes to the control of immune homeostasis and the resolution of inflammation, making it a useful target for research on inhibitory receptor signaling, apoptotic cell recognition, and immune regulation.
Fig. 1 Schematic representation of the molecular structure of human CD300A and CD300C.1
CD300A, encoded by the CD300A gene, functions as an inhibitory immune receptor that suppresses immune cell activation in response to aminophospholipid ligands:
Creative Biolabs offers high-quality CD300A proteins produced using optimized expression systems, including full-length receptor and isolated extracellular domain variants. The CD300A extracellular domain directly mediates aminophospholipid binding, making these proteins suitable for ligand-receptor interaction studies and related molecular characterization. Studies of CD300A inhibitory signaling require appropriate systems containing the cytoplasmic ITIM motifs and associated phosphatases. All CD300A proteins undergo strict quality control to support consistent performance across applicable research platforms.
Not finding the protein product you need? Contact us to start your one-stop custom service!
Creative Biolabs provides custom-engineered CD300A stable cell lines, including overexpression and blank control models. These cell lines are optimized for studies of inhibitory receptor signaling and immune cell regulation. Each cell line undergoes stringent validation to ensure stable expression profiles and consistent functional performance in diverse experimental contexts.
Not finding the stable cell line product you need? Contact us to start your one-stop custom service!
High-specificity recombinant antibodies targeting CD300A are developed using antibody engineering technologies for research applications involving CD300A expression and localization. These antibodies can be used in studies of CD300A distribution on immune cells and may also support characterization of CD300A ligand interactions in combination with appropriate aminophospholipid detection reagents.
Not finding the recombinant antibody product you need? Contact us to start your one-stop custom service!
Beyond catalog products, Creative Biolabs offers specialized custom services for CD300A research:
CD300A is an inhibitory immune receptor that binds the aminophospholipids phosphatidylethanolamine and phosphatidylserine and suppresses immune cell activation through ITIM-mediated signaling.
CD300A is a core inhibitory receptor controlling natural killer cell, B cell, T cell, and myeloid cell responses, and studying it informs the molecular mechanisms of inhibitory signaling and apoptotic cell recognition.
No, all CD300A products and services are strictly for research use only, not intended for clinical diagnosis or treatment.
Offerings include full-length CD300A proteins, custom CD300A stable cell lines, and CD300A-specific recombinant antibodies for inhibitory immune receptor research.
CD300A products are suitable for studies of aminophospholipid binding, inhibitory receptor signaling, apoptotic cell recognition, and immune cell regulation.